TLDR
- SLS climbs above $3 as REGAL Phase 3 AML trial nears final survival analysis
- SELLAS stock shows strength as REGAL trial events approach required threshold
- SLS gains momentum with Phase 3 AML data catalyst drawing closer
- SELLAS advances REGAL trial timeline as shares rebound with strong volume
- SLS trades higher as Phase 3 AML survival study progresses toward final readout
- SELLAS Life Sciences (SLS) Shows Bullish Momentum Ahead of Pivotal AML Data Readout
SELLAS Life Sciences Group Inc. (SLS) traded near $3.17, rising over 10% during an active intraday session.
SELLAS Life Sciences Group, Inc., SLS
Stock showed strong buying pressure as technical momentum aligned with a key clinical trial update. The move reflects renewed confidence ahead of an important Phase 3 AML data milestone.
The company confirmed progress in its REGAL Phase 3 trial evaluating galinpepimut-S in acute myeloid leukemia.Study reached seventy-two pooled survival events toward the required eighty. As a result, the final overall survival analysis now appears increasingly near.
The REGAL study focuses on AML patients in second complete remission following salvage therapy. Trial remains blinded, and no efficacy or survival outcomes were reviewed. Therefore, the update did not alter planned statistical analyses or trial integrity.
REGAL Phase 3 Trial Progress Supports Fundamental Outlook
SELLAS continues to advance its registrational REGAL trial without modification following prior IDMC guidance. The monitoring committee recommended trial continuation after reviewing safety and study conduct. The trial has maintained momentum toward its predefined event-driven endpoint.
The study triggers its final analysis once eighty total survival events occur. Survival timelines appear longer than originally expected across the patient population. The delay reflects patient outcomes rather than operational setbacks.
REGAL evaluates galinpepimut-S as a maintenance therapy targeting the WT1 protein. WT1 expression appears across multiple tumor types, including hematologic malignancies. The program holds relevance beyond a single AML subset.
Intraday Technical Strength Reinforces Market Confidence
SLS displayed notable volatility early in the session before establishing higher intraday lows. Subsequently, the stock reclaimed the $3.00 level after briefly dipping into the high $2 range. This recovery indicated strong demand absorbing short-term selling pressure.
Price action later stabilized below the $3.25 area, which formed near-term resistance. The stock maintained support above $2.87, a key reclaimed intraday level. Technical structure remained constructive throughout the session. Volume expansion accompanied the rebound, reinforcing the strength of the move. Additionally, sustained trading above $3 reflected regained bullish control. Together, these signals supported the broader fundamental narrative.
SELLAS Pipeline Adds Broader Context to Near-Term Catalyst
SELLAS continues development of SLS009, a selective CDK9 inhibitor. Early data showed encouraging responses in AML patients with adverse genetic profiles. As such, the pipeline extends beyond a single asset.
The company positions SLS009 as a differentiated molecule with improved tolerability. Importantly, the candidate targets patients with limited therapeutic options. This approach aligns with unmet needs in hematologic malignancies.
SELLAS remains focused on advancing late-stage oncology programs toward meaningful outcomes. The approaching REGAL analysis represents a defining clinical milestone. Recent stock strength reflects both technical recovery and clinical progress.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
